Professor of Chemical Biology

Daniel K. Nomura, Ph.D.

View profile

Professor of Chemical Biology 

Department of Chemistry
University of California, Berkeley

Adjunct Professor 

Department of Pharmaceutical Chemistry
University of California, San Francisco

Director 

Novartis-Berkeley Center for Proteomics
and Chemistry Technologies

Investigator 

Innovative Genomics Institute

Contact

Daniel K. Nomura, Ph.D.
University of California, Berkeley
Innovative Genomics Institute
2151 Berkeley Way, Room 312G
Berkeley, CA 94720
Phone: 510-643-7258
E-mail: dnomura@berkeley.edu

Bio

Dan Nomura is a Professor of Chemical Biology in the Department of Chemistry at the University of California, Berkeley and an Adjunct Professor in the Department of Pharmaceutical Chemistry at UCSF. Since 2017, he has also been the Director of the Novartis-Berkeley Center for Proteomics and Chemistry Technologies focused on using chemoproteomic platforms to tackle the undruggable proteome. He is also Co-Founder and Head of the Scientific Advisory Board of Frontier Medicines.  He earned his B.A. in Molecular and Cell Biology and Ph.D. in Molecular Toxicology at UC Berkeley with Professor John Casida and was a postdoctoral fellow at Scripps Research with Professor Ben Cravatt before returning to Berkeley as a faculty member in 2011. Among his honors are selection as a Searle Scholar, American Cancer Society Research Scholar Award, the Department of Defense Breakthroughs Award, Eicosanoid Research Foundation Young Investigator Award, and the Mark Foundation for Cancer Research ASPIRE award.

Major Research Directions

The Nomura Research Group is focused on reimagining druggability using chemoproteomic platforms to develop transformative medicines. One of the greatest challenges that we face in discovering new disease therapies is that most proteins are considered “undruggable,” in that most proteins do not possess known binding pockets or “ligandable hotspots” that small-molecules can bind to modulate protein function. Our research group addresses this challenge by advancing and applying chemoproteomic platforms to discover and pharmacologically target unique and novel ligandable hotspots for disease therapy. We currently have three major research directions. Our first major focus is on developing and applying chemoproteomics-enabled covalent ligand discovery approaches to rapidly discover small-molecule therapeutic leads that target unique and novel ligandable hotspots for undruggable protein targets and pathways. Our second research area focuses on using chemoproteomic platforms to expand the scope of targeted protein degradation technologies. Our third research area focuses on using chemoproteomics-enabled covalent ligand discovery platforms to develop new induced proximity-based therapeutic modalities. Collectively, our lab is focused on developing next-generation transformative medicines through pioneering innovative chemical technologies to overcome challenges in drug discovery.

Biography
  • Professor, University of California, Berkeley in the Departments of Chemistry, Molecular and Cell Biology, and Nutritional Sciences and Toxicology (2019-current)
  • Investigator, Innovative Genomics Institute (2019-current)
  • Co-Founder and Chair of the Scientific Advisory Board of Frontier Medicines (2019-current)
  • Director, Novartis-Berkeley Center for Proteomics and Chemistry Technologies (2017-current)
  • Associate Professor, University of California, Berkeley in the Departments of Chemistry, Molecular and Cell Biology, and Nutritional Sciences and Toxicology (2015-2019)
  • Assistant Professor, University of California, Berkeley in the Department of Nutritional Sciences and Toxicology (2011-2015)
  • Postdoctoral Fellow at Scripps Research (2008-2011) in Chemical Biology (Advisor: Ben Cravatt)
  • Ph.D. University of California, Berkeley (2004-2008) in Molecular Toxicology (Advisor: John Casida)
  • B.A. University of California, Berkeley (1999-2003) in Molecular and Cell Biology (Advisor: John Casida)

Help us advance
our research